AstraZeneca Covid Vaccine Get Closer to Deliver to Thailand, Analysts Recomm. Global Play
AstraZeneca announced the samples from test batches of the Covid-19 vaccine made by Siam Bioscience had passed quality testing and the delivery is getting closer.
Capital Nomura Securities (CNS) expected the SET Index this week to move narrowly in the range of 1,550-1,606. Major issue in the market to monitor is the 1Q21 results announcement of listed companies, particularly the Real Sector. As of prior, about 22 companies had reported their operating results, mostly in line with consensus forecast.
The movement of Thai market lately has been strongly dependent on the number of Covid-19 daily cases. Hence, CNS recommended avoiding Domestic Play, in particular service and tourism sectors.
If there is a market correction, CNS suggested to accumulate stocks that tend to outperform the market such as Global Play like SCGP, IRPC, TVO, TU, HANA, KCE and CPF, and Farm Income Recovery like SCC and DCC.
Kasikorn Securities, meanwhile, estimated the SET between May 10-14 to move in the range of 1,560-1,620, recommending to closely keep eyes on the vaccine distribution situation.
AstraZeneca (Thailand) Ltd., announced on May 9, 2021, that the samples from test batches of the Covid-19 vaccine made by Siam Bioscience had passed quality testing at AstraZeneca’s designated laboratories in Europe and in the U.S.
Mr. James Teague, Country President, AstraZeneca (Thailand) said: “We have seen significant and promising progress in AstraZeneca’s Covid-19 vaccine development in Thailand during past weeks. First, the Thai Food and Drug Administration approved Siam Bioscience as a manufacturing facility for the Covid-19 Vaccine AstraZeneca. Last week, samples of COVID-19 Vaccine AstraZeneca made by Siam Bioscience passed the full tests and standard set by the Department of Medical Sciences (DMS) covering requirements such as chemical composition and safety. And today, I am happy to be able to inform you that the samples from test batches of the COVID-19 vaccine made by Siam Bioscience have passed quality testing at AstraZeneca’s designated laboratories in Europe and in the U.S. This significant progress means that we are getting closer to delivering the first batch of the vaccine to the government of Thailand.”